Vol. 6 No. 2 (2026)
Reimbursement Reviews

Risperidone (Longavo)

decorative image of the issue cover

Published February 27, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Risperidone for extended-release injectable suspension (risperidone ER, Longavo), prefilled syringe, 50 mg, 75 mg, 100 mg, 125 mg, subcutaneous injection.
  • Indication: For the treatment of schizophrenia in adults.